These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 35267576)

  • 1. Targeting IGF2BP2 Promotes Differentiation of Radioiodine Refractory Papillary Thyroid Cancer via Destabilizing RUNX2 mRNA.
    Sa R; Liang R; Qiu X; He Z; Liu Z; Chen L
    Cancers (Basel); 2022 Mar; 14(5):. PubMed ID: 35267576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IGF2BP2-dependent activation of ERBB2 signaling contributes to acquired resistance to tyrosine kinase inhibitor in differentiation therapy of radioiodine-refractory papillary thyroid cancer.
    Sa R; Liang R; Qiu X; He Z; Liu Z; Chen L
    Cancer Lett; 2022 Feb; 527():10-23. PubMed ID: 34896211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AhR Antagonist Promotes Differentiation of Papillary Thyroid Cancer
    Sa R; Guo M; Liu D; Guan F
    Front Pharmacol; 2021; 12():795386. PubMed ID: 35002727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. m6A reader IGF2BP2 promotes lymphatic metastasis by stabilizing DPP4 in papillary thyroid carcinoma.
    Wang W; Ding Y; Zhao Y; Li X
    Cancer Gene Ther; 2024 Feb; 31(2):285-299. PubMed ID: 38102465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and validation of m
    Wang X; Fu X; Zhang J; Xiong C; Zhang S; Lv Y
    Cancer Cell Int; 2020; 20():203. PubMed ID: 32514248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IGF2BP2 Promotes Liver Cancer Growth Through an m6A-FEN1-Dependent Mechanism.
    Pu J; Wang J; Qin Z; Wang A; Zhang Y; Wu X; Wu Y; Li W; Xu Z; Lu Y; Tang Q; Wei H
    Front Oncol; 2020; 10():578816. PubMed ID: 33224879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer.
    Romei C; Ciampi R; Faviana P; Agate L; Molinaro E; Bottici V; Basolo F; Miccoli P; Pacini F; Pinchera A; Elisei R
    Endocr Relat Cancer; 2008 Jun; 15(2):511-20. PubMed ID: 18509003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IGF2BP2 Regulates MALAT1 by Serving as an N6-Methyladenosine Reader to Promote NSCLC Proliferation.
    Han L; Lei G; Chen Z; Zhang Y; Huang C; Chen W
    Front Mol Biosci; 2021; 8():780089. PubMed ID: 35111811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stabilization of UCA1 by N6-methyladenosine RNA methylation modification promotes colorectal cancer progression.
    He RZ; Jiang J; Hu X; Lei M; Li J; Luo W; Duan L; Hu Z; Mo YY; Luo DX; Peng WX
    Cancer Cell Int; 2021 Nov; 21(1):616. PubMed ID: 34809621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IGF2BP2 knockdown suppresses thyroid cancer progression by reducing the expression of long non-coding RNA HAGLR.
    Dong L; Geng Z; Liu Z; Tao M; Pan M; Lu X
    Pathol Res Pract; 2021 Sep; 225():153550. PubMed ID: 34340128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. m6A modification promotes miR-133a repression during cardiac development and hypertrophy via IGF2BP2.
    Qian B; Wang P; Zhang D; Wu L
    Cell Death Discov; 2021 Jun; 7(1):157. PubMed ID: 34226535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteomic analysis of radioiodine-refractory differentiated thyroid cancer identifies CHI3L1 upregulation in association with dysfunction of the sodium-iodine symporter.
    Li Y; Hu F; Deng J; Huang X; Zhou C; Wu M; Duan D
    Oncol Lett; 2023 Jan; 25(1):36. PubMed ID: 36589664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Significance of an m6A Reader Gene,
    Deng X; Jiang Q; Liu Z; Chen W
    Front Mol Biosci; 2020; 7():68. PubMed ID: 32391379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcription Factor HOXA9 is Linked to the Calcification and Invasion of Papillary Thyroid Carcinoma.
    Jin Y; Kim HK; Lee J; Soh EY; Kim JH; Song I; Chung YS; Choi YJ
    Sci Rep; 2019 May; 9(1):6773. PubMed ID: 31043660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LARP7 in papillary thyroid carcinoma induces NIS expression through suppression of the SHH signaling pathway.
    Sui X; Sui Y; Wang Y
    Mol Med Rep; 2018 Jun; 17(6):7521-7528. PubMed ID: 29620212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of IGF2BP2, an m6A reader gene, in human metabolic diseases and cancers.
    Wang J; Chen L; Qiang P
    Cancer Cell Int; 2021 Feb; 21(1):99. PubMed ID: 33568150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LINC00460/DHX9/IGF2BP2 complex promotes colorectal cancer proliferation and metastasis by mediating HMGA1 mRNA stability depending on m6A modification.
    Hou P; Meng S; Li M; Lin T; Chu S; Li Z; Zheng J; Gu Y; Bai J
    J Exp Clin Cancer Res; 2021 Feb; 40(1):52. PubMed ID: 33526059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aberrant promoter methylation in overexpression of CITED1 in papillary thyroid cancer.
    Sassa M; Hayashi Y; Watanabe R; Kikumori T; Imai T; Kurebayashi J; Kiuchi T; Murata Y
    Thyroid; 2011 May; 21(5):511-7. PubMed ID: 21449767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of BRAF(V600E) mutation on Na(+)/I(-) symporter expression in papillary thyroid carcinoma.
    Dong H; Shen WZ; Yan YJ; Yi JL; Zhang L
    J Huazhong Univ Sci Technolog Med Sci; 2016 Feb; 36(1):77-81. PubMed ID: 26838744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FLOT1, stabilized by WTAP/IGF2BP2 mediated N6-methyladenosine modification, predicts poor prognosis and promotes growth and invasion in gliomas.
    Song T; Hu Z; Zeng C; Luo H; Liu J
    Heliyon; 2023 Jun; 9(6):e16280. PubMed ID: 37260902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.